Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 21, 2015 (12 years ago)

Ketorolac Tromethamine Ophthalmic Solution

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulate Matter: lot is not meeting the specification limit for number of particles present in the solution.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Ketorolac Tromethamine Ophthalmic Solution, 0.5%, 3 mL bottle, Rx only, Distributed by: Caraco Pharmaceutical Laboratories Ltd., 1150 Elijah Mccoy Drive, Detroit, MI 48202; Manufactured at: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India; NDC 41616-219-90, UPC 3 41616 21990 6.

Affected NDC 41616-0219-90

Compare with the code on your package — it is the most precise check available.

Drug: Ketorolac Category: Eye Drops & Ophthalmic

Recalling firm
Sun Pharma Global Fze
NDC code
41616-219-90
Origin
N/A, United Arab Emirates
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0394-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ketorolac recalls

See all

Other recalls by Sun Pharma Global Fze

All 2015 recalls
Class II · Moderate risk

Alendronate Sodium Tablets

Failed Impurities/Degradation Specifications: Observed levels of highest unknown impurity exceeding specification limit at the 3 month stability time point.

Terminated Impurity / degradation Sun Pharma Global Fze NDC 41616-638-68 D-0735-2016
Class III · Low risk

buPROPion Hydrochloride Extended-¿release Tablets USP

Failed Dissolution Specification: During analysis of the 18 month long term stability testing, it was noticed that the drug release results at the 4 hour time point are not meeting specifications.

Terminated Dissolution failure Sun Pharma Global Fze NDC 47335-738-86 D-1345-2015
Class II · Moderate risk

Levetiracetam

Failed Dissolution Specifications: 6 month time point.

Terminated Dissolution failure Sun Pharma Global Fze D-0386-2015